Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
暂无分享,去创建一个
Marc P. Bonaca | David A. Morrow | Benjamin M. Scirica | Jindrich Spinar | E. Braunwald | D. Morrow | S. Murphy | B. Scirica | K. Fox | P. Théroux | G. Magnani | J. Nicolau | Eugene Braunwald | Sabina A. Murphy | Giulia Magnani | Anthony J. Dalby | Keith A. A. Fox | José Carlos Nicolau | Ton Oude Ophuis | Pierre Theroux | J. Špinar | T. Oude Ophuis | A. Dalby | P. Théroux
[1] Marc P. Bonaca,et al. Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke , 2013, Stroke.
[2] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[3] L. Neyses,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[4] Marc P. Bonaca,et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.
[5] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[6] Vivian Gu,et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. , 2008, The New England journal of medicine.
[7] R. Mahmoud,et al. Left ventricular outflow tract obstruction in Tako-Tsubo syndrome: Stress cardiomyopathy or hypertrophic cardiomyopathy? , 2009 .
[8] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[9] Jeroen J. Bax,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .
[10] Marc P. Bonaca,et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.
[11] H. Diener,et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.
[12] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[13] C. Coffey,et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. , 2012, The New England journal of medicine.
[14] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[15] Marc P. Bonaca,et al. Vorapaxar in Patients With Peripheral Artery Disease: Results from TRA2°P-TIMI 50 , 2013 .
[16] Marc P. Bonaca,et al. SCH 530348: a novel oral thrombin receptor antagonist. , 2009, Future cardiology.
[17] Marc P. Bonaca,et al. Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2°P-TIMI 50 , 2013, Circulation.